Skip to main content
OpenTrials
Completed

NCT Number: NCT03022903

Blue Light Photodynamic Therapy Treatment for Distal and Lateral Subungual Toenail Onychomycosis

This research study will evaluate the safety and efficacy of using blue light photodynamic therapy (PDT) for treating toenail fungal infections.

Completed

Looking for future studies?

Notify Me

Key information

Age range

19 year–70 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Dermatology at the Whitaker Clinic

Birmingham, Alabama, 35249, United States

About this study

This research study will evaluate the safety and efficacy of using blue light photodynamic therapy (PDT) for treating toenail fungal infections.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients older than 19 and younger than 70 years
  • Give written informed consent prior to any study procedures being conducted, and candidates will authorize the release and use of protected health information (PHI)
  • Diagnosed with distal lateral subungual onychomycosis (DLSO) of the great toe with both positive potassium hydroxide (KOH) and positive culture growth of Trichophyton rubrum
  • No topical treatment for DLSO in the preceding 2 weeks and no oral treatment for DLSO (itraconazole or terbinafine) in the preceding 8 weeks
  • At lease 20% of target great toe nail affected

Exclusion criteria

  • Unable to comply with the protocol (as defined y the investigator; i.e. drug or alcohol abuse or history of noncompliance)
  • Patients with active nail disease that would confound evaluation of DLSO, such as psoriasis
  • Patients with greater than 6 toenails affected
  • Over 90% of target great toe affected
  • Evidence of fingernail fungal infection
  • Patients with recurrent serious infections or have been hospitalized in the preceding 6 months for infection
  • Patients with known history of HIV or hepatitis B or C infection
  • Patients with severe, progressive, or uncontrolled with renal, hepatic, hematological, gastrointestinal, metabolic, endocrine, pulmonary, cardiovascular, or neurologic disease
  • Any subject who, in the opinion of the investigator, will be uncooperative or unable to comply with study procedures

Treatment and study plan

Aminolevulinic Acid (ALA)

Procedure

Photosensitizing

Other names: ALA is a topical drug used in the administration of PDT.

Primary outcomes

  1. Number of subjects diagnosed with presence of subungual culture after 3rd treatment session

    Time frame: 3 weeks after baseline

    Based on presence of fungal infection from culture assessment

  2. Number of subjects with clinical cure based on photographs after the 3rd treatment session

    Time frame: 3 weeks after baseline

    Based on visual assessment of photographs: presence or absence of fungal infection

Secondary outcomes

  1. Compare rates of mycological and clinical cure after three treatments between two groups with different ALA incubation times

    Time frame: 3 weeks after baseline

  2. Evaluate the durability of treatment outcomes with subungual culture and photographs at 24 weeks

    Time frame: 24 weeks after first treatment

  3. Evaluate tolerability to treatment using a Visual Analog Scale (VAS) pain scale questionnaire at each treatment visit

    Time frame: 1 week after baseline

  4. Evaluate tolerability to treatment using a Visual Analog Scale (VAS) pain scale questionnaire at each treatment visit

    Time frame: 2 weeks after baseline

  5. Evaluate tolerability to treatment using a Visual Analog Scale (VAS) pain scale questionnaire at each treatment visit

    Time frame: 3 weeks after baseline

Sponsors and collaborators

Lead sponsor

University of Alabama at Birmingham

Other

Collaborators

  • DUSA Pharmaceuticals, Inc.

Registry information

Important dates

Study start
2015
Primary completion
2019
Study completion
2021
First posted
Jan 18, 2017
Registry last updated
Feb 7, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.